Excyte Biopharma Ltd

This study is testing a new drug called YK012 for adults with moderate to severe lupus. The main goals are to check the drug's safety, how the body processes it, and to see if it can help reduce lupus disease activity. Participants will receive the drug while continuing their sta…

This study is testing a new drug called YK012 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or hasn't responded to previous treatments. The trial has two parts: first finding the safest dose, then seeing if the drug shows signs of fighting the canc…

This is the first time a new drug called YK012 is being tested in people. The study aims to find a safe dose and see if it helps patients with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers will enroll about 48 adults to check …

This is the first human study to test the safety and early effects of a new drug called YK012 for primary membranous nephropathy, a kidney disease where the body's immune system attacks the kidneys. The trial will enroll 72 adults with this condition to find the safest dose and s…

This is the first study in people to test a new drug called YKST02 for multiple myeloma, a type of blood cancer, that has come back or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. The drug is designed to h…